Article
Top 5 Most-Read Comprehensive Genomic Profiling Articles of 2021
Author(s):
The top 5 most-read comprehensive genomic profiling articles of 2021 on AJMC.com largely focused on the use of liquid biopsy and how biomarkers can offer providers new ways to help predict treatment-related outcomes and identify therapeutic targets.
In 2021, the top 5 most-read comprehensive genomic profiling (CGP) articles of 2021 on AJMC.com mostly focused on the use of genomic profiling as a means to identify possible treatment-related outcomes and targetable biomarkers. Two pieces addressed how liquid biopsy can be used to improve providers’ ability to make treatment decisions for patients with non–small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).
The year also brought news about Foundation Medicine’s partnership with Epic to streamline providers’ decision-making capabilities by integrating CGP and other testing services into a central location.
5. Liquid Biopsy of Cerebrospinal Fluid May Improve Treatment Considerations in NSCLC
Researchers found that the unique genomic variations found in cerebrospinal fluid might be leveraged as a liquid biopsy to effectively and safely improve providers' ability to make decisions regarding treatment for patients with NSCLC with leptomeningeal metastasis. The results may represent a better surrogate endpoint for molecular analysis in patients with NSCLC whose tumor tissues are unavailable.
4. Study: Serial Liquid Biopsy May Be Useful in Identifying RAS Genetic Mutations in mCRC
Serial liquid biopsies could serve as a useful tool for identifying changes in the mutation status of genes in the RAS family in patients with mCRC who have undergone antiangiogenic therapy, according to study results. The retrospective analysis supported the notion that mCRC is an ever-changing condition and that mutational changes in RAS genes may be induced by antiangiogenic therapy in patients with mCRC.
3. Study Finds Predictive Biomarkers for Chemo-Radiotherapy Toxicity, Efficacy in NSCLC
Using CGP, several predictive biomarkers could be leveraged to predict efficacy and toxicity of chemo-radiotherapy in patients with NSCLC, according to these findings from September. The results also showed that progression-free and overall survival were associated with some of the identified genes and that chemo-radiotherapy was limited by individual variations in radiosensitivity and the risk of radiation-induced thoracic toxicity.
2. Pathologists Discuss Actionable Mutations and Testing in Metastatic Breast Cancer
Diagnostic tools and options in patients with recurrent or advanced metastatic breast cancer were presented at the National Comprehensive Cancer Network 2021 Virtual Congress: Biomarkers in Solid Tumors. Kimberly H Allison, MD, director of Breast Pathology at Stanford Cancer Institute (SCI), and Melinda L Telli, MD, director of the Breast Cancer Program at SCI, used real-world examples to demonstrate how genetic profiling in these cancers could yield actionable, targetable biomarkers.
1. Foundation Medicine, Epic Partner on Access to Genomic Profiling in EHRs
Foundation Medicine announced a partnership to integrate its CGP and other testing services with Epic’s electronic health record (EHR) system, which enables providers to electronically order genomic testing for patients within the Epic network. The optimized integration will support oncology practices, academic medical centers, and other health systems by consolidating clinical and genetic information in a singular location, allowing providers to make more streamlined clinical decisions.
ICYMI: Highlights From the 2022 American Academy of Dermatology Meeting
